Global Etoposide Market: Description
Etoposide is a derivative of epipodophyllotoxins that are derived from Mandragora officianarum (plant). Its chemical name is 4'-demethyl-epipodophylotoxin 9-[4,6-O-(R)-ethylidene-?-D-glucopyranoside] and it was introduced in the market in 1970. Currently, it is utilized extensively in manufacturing drugs that help treat various human malignant diseases such as testicular cancer, lymphomas (Hodgkin, non-Hodgkin), leukemia and lung cancer. Other diseases that are treated by consumption of etoposide include Ewing sarcoma, Kaposi disease, rhabdomyosarcoma, soft tissue sarcoma, pediatric brain tumors, gastric cancer, Wilms tumor, multiple myeloma, hepatoma, adenocarcinoma and uterine cancer.
Etoposide acts by inhibiting the activity of topoisomerase II which is responsible for uncoiling of deoxyribonucleic acid (DNA) and thus affects the deoxyribonucleic acid (DNA) replication and repair. Etoposide is usually administered in combination with various antineoplastic drugs such as cisplatin that have different modes of action. Etoposide is administered in the patient’s body through oral and intravenous routes. Intravenous administration of etoposide is given under the supervision of a doctor since overdose of the same might result in malfunctioning of human body. Etoposide solution for injection is available in 5 mL vial, 25 mL vial and 50 mL vial, and the dose is 20 mg/mL. Etoposide injections are usually given to patients whose cancer condition have not improved or have worsened post radiation treatment or other medications.
Global Etoposide Market: Major Products
Etopophos, Toposar and Vepesid are some of the branded versions of the Etoposide. Among all these, Etopophos accounts for the largest revenue share in the total etoposide market. Rising incidence of lung cancer has been considered as one of the major factors driving the market for etoposide. According to the American Lung Association (ALA), an estimated 159,260 people with lung cancer are expected to die in the American region in 2014 that will account for approximately 27% of all cancer deaths in the same year. Also, increasing incidence of Ewing sarcoma will propel the growth of etoposide market.
Global Etoposide Market: Drivers and Restraints
The increasing number of acquired immune deficiency syndrome (AIDS) patients across the globe will further drive the growth of etoposide market as people with AIDS are at the high risk of developing Kaposi’s sarcoma. It has been estimated by the World Health Organization that in 2012, around 35.3 million people were living with AIDS worldwide; of these around 1.6 million people died. AIDS also increases the risk for Hodgkin and non-Hodgkin syndrome. Increasing number of patients suffering with gastric cancer will also augment the growth of etoposide market. Various epidemiological sources indicate that around 1 million people suffer from gastric cancer every year across the globe. Despite all the advantages, the growth of etoposide market might get hampered due to the side effects associated with the administration of etoposide. Difficulty in breathing or swallowing, seizures, hives, constipation, hair loss and unusual tiredness or weakness are some of the side-effects that are associated with etoposide.
Global Etoposide Market: Geographical Dynamics
North America accounted for the largest revenue share of the total etoposide market in 2012 owing to the presence of major manufacturing companies in the region along with the improving governmental initiatives for the development and manufacturing of etoposide. Asia-Pacific is expected to show highest CAGR during the forecast period. This growth is attributed to rising incidences of various diseases such as uterine cancer, multiple myeloma, hepatoma and lymphoma in the region. Increasing government funding for the R&D of etoposide will further drive the growth of etoposide market in the region. Major players operating in the market includes Pharmedic Laboratories Pvt. Ltd, Teva Pharmaceutical Industries Ltd, Ben Venue Laboratories, and Accord Healthcare, Inc. among other significant players.
The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology, types, and applications.
The study is a source of reliable data on:
The regional analysis covers:
The report has been compiled through extensive primary research (through interviews, surveys, and observations of seasoned analysts) and secondary research (which entails reputable paid sources, trade journals, and industry body databases). The report also features a complete qualitative and quantitative assessment by analyzing data gathered from industry analysts and market participants across key points in the industry’s value chain.
A separate analysis of prevailing trends in the parent market, macro- and micro-economic indicators, and regulations and mandates is included under the purview of the study. By doing so, the report projects the attractiveness of each major segment over the forecast period.
Highlights of the report:
Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.
Please fill the Request TOC form below.
Make an enquiry before buying this Report
Please fill the enquiry form below.